What is FEops?
Headquartered in Gent, Belgium, and founded in 2009, FEops operates at the intersection of medical technology and data science. The company specializes in providing physicians with unique digital tools designed to optimize patient outcomes by ensuring the right patients receive the right technology at the right time. By focusing on the precision treatment of heart disease, FEops addresses a critical gap in clinical decision support, effectively reducing procedural risks and improving the overall quality of life for patients undergoing cardiovascular interventions. Its market position is defined by its commitment to evidence-based innovation and its ability to integrate seamlessly into existing hospital infrastructures.
How much funding has FEops raised?
FEops has raised a total of $12M across 3 funding rounds:
Series A
$1.5M
Series B
$7.2M
Debt
$3.3M
Series A (2015): $1.5M with participation from Capricorn Venture Partners and PMVenture
Series B (2017): $7.2M led by Capricorn Venture Partners, PMV, and Valiance
Debt (2022): $3.3M supported by The European Innovation Council
Key Investors in FEops
Capricorn Venture Partners
An independent manager specializing in venture capital and growth equity, focusing on innovative companies within the digital, health, and clean technology sectors.
PMV
A strategic financial partner that supports the growth of start-ups and mature SMEs through tailored financing solutions and advisory services in life sciences and infrastructure.
Valiance
A global investment firm dedicated to collaborating with impactful technology businesses to drive social progress and improve patient quality of life.
What's next for FEops?
With the recent infusion of capital, FEops is well-positioned to accelerate its product development roadmap and expand its footprint in the global digital health market. The company is expected to leverage these resources to enhance its simulation capabilities, potentially broadening its application across various cardiovascular procedures. As the healthcare industry increasingly shifts toward value-based care and personalized medicine, FEops' focus on data-driven clinical insights will likely remain a key differentiator. Future strategic initiatives will likely prioritize regulatory expansion and the scaling of its commercial operations to meet the growing demand for precision-guided medical interventions.
See full FEops company page
